{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:19Z","timestamp":1792788079143,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004917","name":"CPRIT","doi-asserted-by":"crossref","award":["RP230446"],"award-info":[{"award-number":["RP230446"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Institutional Research Grant (IRG), MDACC","award":["2022-00061331-Y1"],"award-info":[{"award-number":["2022-00061331-Y1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (\n                    <jats:italic>uveal<\/jats:italic>\n                    ) and brain (\n                    <jats:italic>cutaneous<\/jats:italic>\n                    ), particularly in advanced melanoma stages. The increasing interest in utilizing LDRT for secondary metastatic sites of uveal, mucosal, or cutaneous melanomas underscores its potential efficacy in combination with various immunotherapies. This comprehensive review traverses the journey from laboratory research to clinical applications, elucidating LDRT\u2019s immunomodulatory role on the tumor immune microenvironment (TIME) and systemic immune responses. We meticulously examine the preclinical evidence and ongoing clinical trials, throwing light on the promising prospects of LDRT as a complementary therapy in melanoma treatment. Furthermore, we explore the challenges associated with LDRT\u2019s integration into combination therapies, addressing crucial factors such as optimal dosage, fractionation, treatment frequency, and synergy with other pharmacological agents. Considering its low toxicity profile, LDRT presents a compelling case for application across multiple lesions, augmenting the antitumor immune response in poly-metastatic disease scenarios. The convergence of LDRT with other disciplines holds immense potential for developing novel radiotherapy-combined modalities, paving the way for more effective and personalized treatment strategies in melanoma and beyond. Moreover, the dose-related toxicities of immunotherapies may be reduced by synergistic amplification of antitumor efficacy with LDRT.\n                  <\/jats:p>","DOI":"10.1186\/s13046-025-03281-2","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T22:53:07Z","timestamp":1738191187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects"],"prefix":"10.1186","volume":"44","author":[{"given":"Zahid","family":"Rafiq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyo","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hampartsoum B.","family":"Barsoumian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gohar S.","family":"Manzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Leuschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Masrorpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-5230","authenticated-orcid":false,"given":"Nahum","family":"Puebla-Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"3281_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejcsup.2013.07.012","volume":"11","author":"Z Ali","year":"2013","unstructured":"Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. EJC Suppl. 2013;11:81\u201391. https:\/\/doi.org\/10.1016\/j.ejcsup.2013.07.012.","journal-title":"EJC Suppl"},{"key":"3281_CR2","doi-asserted-by":"publisher","first-page":"778459","DOI":"10.3389\/fimmu.2021.778459","volume":"12","author":"J Bulgarelli","year":"2021","unstructured":"Bulgarelli J, et al. Radiotherapy and High-Dose Interleukin-2: clinical and immunological results of a proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. Front Immunol. 2021;12:778459. https:\/\/doi.org\/10.3389\/fimmu.2021.778459.","journal-title":"Front Immunol"},{"key":"3281_CR3","doi-asserted-by":"publisher","unstructured":"Barsoumian HB, et al. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-000537.","DOI":"10.1136\/jitc-2020-000537"},{"key":"3281_CR4","doi-asserted-by":"publisher","unstructured":"Blach J, Wojas-Krawczyk K, Nicos M, Krawczyk P. Failure of immunotherapy-the molecular and immunological origin of immunotherapy resistance in lung cancer. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22169030.","DOI":"10.3390\/ijms22169030"},{"key":"3281_CR5","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S89591","volume":"11","author":"BA Krantz","year":"2017","unstructured":"Krantz BA, Dave N, Komatsubara KM, Marr BP, Carvajal RD. Uveal melanoma: epidemiology, etiology, and treatment of primary disease. Clin Ophthalmol. 2017;11:279\u201389. https:\/\/doi.org\/10.2147\/OPTH.S89591.","journal-title":"Clin Ophthalmol"},{"key":"3281_CR6","doi-asserted-by":"publisher","first-page":"1279387","DOI":"10.3389\/fimmu.2023.1279387","volume":"14","author":"KER Smith","year":"2023","unstructured":"Smith KER, et al. A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses. Front Immunol. 2023;14:1279387. https:\/\/doi.org\/10.3389\/fimmu.2023.1279387.","journal-title":"Front Immunol"},{"key":"3281_CR7","doi-asserted-by":"publisher","unstructured":"Xu Y, et al. Epidemiological study of uveal melanoma from US surveillance, epidemiology, and end results program (2010\u20132015). J Ophthalmol. 2020;2020(3614039). https:\/\/doi.org\/10.1155\/2020\/3614039.","DOI":"10.1155\/2020\/3614039"},{"key":"3281_CR8","doi-asserted-by":"publisher","unstructured":"Steininger J, et al. Systemic therapy of metastatic melanoma: on the road to cure. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13061430.","DOI":"10.3390\/cancers13061430"},{"key":"3281_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s40425-019-0800-0","volume":"7","author":"MV Heppt","year":"2019","unstructured":"Heppt MV, et al. Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center study. J Immunother Cancer. 2019;7:299. https:\/\/doi.org\/10.1186\/s40425-019-0800-0.","journal-title":"J Immunother Cancer"},{"key":"3281_CR10","doi-asserted-by":"publisher","unstructured":"Szeligo BM, Ivey AD, Boone BA. Poor response to checkpoint immunotherapy in uveal melanoma highlights the persistent need for innovative regional therapy approaches to manage liver metastases. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13143426.","DOI":"10.3390\/cancers13143426"},{"key":"3281_CR11","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41416-023-02361-4","volume":"129","author":"MM Wang","year":"2023","unstructured":"Wang MM, Coupland SE, Aittokallio T, Figueiredo CR. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br J Cancer. 2023;129:1212\u201324. https:\/\/doi.org\/10.1038\/s41416-023-02361-4.","journal-title":"Br J Cancer"},{"key":"3281_CR12","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-021-00247-z","volume":"2","author":"PMK Westcott","year":"2021","unstructured":"Westcott PMK, et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat Cancer. 2021;2:1071\u201385. https:\/\/doi.org\/10.1038\/s43018-021-00247-z.","journal-title":"Nat Cancer"},{"key":"3281_CR13","doi-asserted-by":"publisher","first-page":"915094","DOI":"10.3389\/fimmu.2022.915094","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, et al. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol. 2022;13:915094. https:\/\/doi.org\/10.3389\/fimmu.2022.915094.","journal-title":"Front Immunol"},{"key":"3281_CR14","doi-asserted-by":"publisher","first-page":"7709","DOI":"10.1038\/s41467-023-43462-1","volume":"14","author":"S Li","year":"2023","unstructured":"Li S, et al. Low-dose radiotherapy combined with dual PD-L1 and VEGFA blockade elicits antitumor response in hepatocellular carcinoma mediated by activated intratumoral CD8(+) exhausted-like T cells. Nat Commun. 2023;14:7709. https:\/\/doi.org\/10.1038\/s41467-023-43462-1.","journal-title":"Nat Commun"},{"key":"3281_CR15","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.ccr.2013.09.014","volume":"24","author":"F Klug","year":"2013","unstructured":"Klug F, et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)\/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013;24:589\u2013602. https:\/\/doi.org\/10.1016\/j.ccr.2013.09.014.","journal-title":"Cancer Cell"},{"key":"3281_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of Cancer: New dimensions. Cancer Discov. 2022;12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1059.","journal-title":"Cancer Discov"},{"key":"3281_CR17","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1158\/2159-8290.CD-21-0003","volume":"12","author":"FG Herrera","year":"2022","unstructured":"Herrera FG, et al. Low-dose Radiotherapy reverses Tumor Immune Desertification and Resistance to Immunotherapy. Cancer Discov. 2022;12:108\u201333. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0003.","journal-title":"Cancer Discov"},{"key":"3281_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/ijc.34801","volume":"154","author":"L Zhou","year":"2024","unstructured":"Zhou L, et al. Low-dose radiation therapy mobilizes antitumor immunity: New findings and future perspectives. Int J Cancer. 2024;154:1143\u201357. https:\/\/doi.org\/10.1002\/ijc.34801.","journal-title":"Int J Cancer"},{"key":"3281_CR19","doi-asserted-by":"publisher","unstructured":"Jin JY, et al. Higher radiation dose to the immune cells correlates with worse tumor control and overall survival in patients with stage III NSCLC: a secondary analysis of RTOG0617. Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13246193.","DOI":"10.3390\/cancers13246193"},{"key":"3281_CR20","doi-asserted-by":"publisher","first-page":"100808","DOI":"10.1016\/j.neo.2022.100808","volume":"31","author":"MJ Gough","year":"2022","unstructured":"Gough MJ, Crittenden MR. The paradox of radiation and T cells in tumors. Neoplasia. 2022;31:100808. https:\/\/doi.org\/10.1016\/j.neo.2022.100808.","journal-title":"Neoplasia"},{"key":"3281_CR21","doi-asserted-by":"publisher","first-page":"812210","DOI":"10.3389\/fimmu.2021.812210","volume":"12","author":"K He","year":"2021","unstructured":"He K, et al. Novel use of low-dose Radiotherapy to modulate the Tumor Microenvironment of Liver metastases. Front Immunol. 2021;12:812210. https:\/\/doi.org\/10.3389\/fimmu.2021.812210.","journal-title":"Front Immunol"},{"key":"3281_CR22","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1667\/RADE-20-00237.1","volume":"195","author":"PA Clark","year":"2021","unstructured":"Clark PA, et al. Low-dose Radiation potentiates the propagation of Anti-tumor immunity against Melanoma Tumor in the brain after in situ vaccination at a Tumor outside the brain. Radiat Res. 2021;195:522\u201340. https:\/\/doi.org\/10.1667\/RADE-20-00237.1.","journal-title":"Radiat Res"},{"key":"3281_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.oraloncology.2016.05.002","volume":"58","author":"RJ Davis","year":"2016","unstructured":"Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59\u201370. https:\/\/doi.org\/10.1016\/j.oraloncology.2016.05.002.","journal-title":"Oral Oncol"},{"key":"3281_CR24","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3390\/immuno3010006","volume":"3","author":"HB Barsoumian","year":"2023","unstructured":"Barsoumian HB, et al. The RadScopal technique as an Immune adjuvant to treat Cancer. Immuno. 2023;3:74\u201385.","journal-title":"Immuno"},{"key":"3281_CR25","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.tranon.2023.101710","volume":"35","author":"L Gao","year":"2023","unstructured":"Gao L, Zhang A. Low-dose radiotherapy effects the progression of anti-tumor response. Transl Oncol. 2023;35:101710. https:\/\/doi.org\/10.1016\/j.tranon.2023.101710.","journal-title":"Transl Oncol"},{"key":"3281_CR26","doi-asserted-by":"publisher","first-page":"166789","DOI":"10.1016\/j.bbadis.2023.166789","volume":"1869","author":"J Wang","year":"2023","unstructured":"Wang J, et al. Exploring low-dose radiotherapy to overcome radio-immunotherapy resistance. Biochim Biophys Acta Mol Basis Dis. 2023;1869:166789. https:\/\/doi.org\/10.1016\/j.bbadis.2023.166789.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3281_CR27","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.7150\/thno.32648","volume":"9","author":"OM Ozpiskin","year":"2019","unstructured":"Ozpiskin OM, Zhang L, Li JJ. Immune targets in the tumor microenvironment treated by radiotherapy. Theranostics. 2019;9:1215\u201331. https:\/\/doi.org\/10.7150\/thno.32648.","journal-title":"Theranostics"},{"key":"3281_CR28","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365\u201372. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0115.","journal-title":"Cancer Immunol Res"},{"key":"3281_CR29","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.ijrobp.2020.08.025","volume":"109","author":"RR Patel","year":"2021","unstructured":"Patel RR, et al. Use of Multi-site Radiation Therapy for systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021;109:352\u201364. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.08.025.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3281_CR30","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-20-4632","volume":"27","author":"AM Monjazeb","year":"2021","unstructured":"Monjazeb AM, et al. A randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or Hypofractionated Radiation for patients with metastatic colorectal Cancer. Clin Cancer Res. 2021;27:2470\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4632.","journal-title":"Clin Cancer Res"},{"key":"3281_CR31","doi-asserted-by":"publisher","first-page":"101137","DOI":"10.1016\/j.adro.2022.101137","volume":"8","author":"HB Barsoumian","year":"2023","unstructured":"Barsoumian HB, et al. Radiation Therapy modulates Tumor Physical characteristics to reduce Intratumoral pressure and enhance Intratumoral Drug Delivery and Retention. Adv Radiat Oncol. 2023;8:101137. https:\/\/doi.org\/10.1016\/j.adro.2022.101137.","journal-title":"Adv Radiat Oncol"},{"key":"3281_CR32","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/1078-0432.CCR-18-3518","volume":"26","author":"T Savage","year":"2020","unstructured":"Savage T, Pandey S, Guha C. Postablation Modulation after single high-dose Radiation Therapy improves Tumor Control via enhanced immunomodulation. Clin Cancer Res. 2020;26:910\u201321. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3518.","journal-title":"Clin Cancer Res"},{"key":"3281_CR33","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259\u201371. https:\/\/doi.org\/10.1084\/jem.20052494.","journal-title":"J Exp Med"},{"key":"3281_CR34","doi-asserted-by":"publisher","unstructured":"Patel RB, et al. Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade. Sci Transl Med. 2021;13. https:\/\/doi.org\/10.1126\/scitranslmed.abb3631.","DOI":"10.1126\/scitranslmed.abb3631"},{"key":"3281_CR35","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1046\/j.1359-4117.2003.01093.x","volume":"3","author":"A Safwat","year":"2003","unstructured":"Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M. Low-dose total body irradiation augments the therapeutic effect of interleukin-2 in a mouse model for metastatic malignant melanoma. J Exp Ther Oncol. 2003;3:161\u20138. https:\/\/doi.org\/10.1046\/j.1359-4117.2003.01093.x.","journal-title":"J Exp Ther Oncol"},{"key":"3281_CR36","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.ejca.2004.01.037","volume":"40","author":"A Safwat","year":"2004","unstructured":"Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2. Eur J Cancer. 2004;40:1412\u20137. https:\/\/doi.org\/10.1016\/j.ejca.2004.01.037.","journal-title":"Eur J Cancer"},{"key":"3281_CR37","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2203\/dose-response.07-020.Jin","volume":"5","author":"SZ Jin","year":"2007","unstructured":"Jin SZ, Pan XN, Wu N, Jin GH, Liu SZ. Whole-body low dose irradiation promotes the efficacy of conventional radiotherapy for cancer and possible mechanisms. Dose Response. 2007;5:349\u201358. https:\/\/doi.org\/10.2203\/dose-response.07-020.Jin.","journal-title":"Dose Response"},{"key":"3281_CR38","doi-asserted-by":"publisher","first-page":"E556","DOI":"10.1016\/j.ijrobp.2020.07.1724","volume":"108","author":"Rossetti-Chung","year":"2020","unstructured":"Vezys V. L. N. S. B. N. P. A. S. A. L. C. N. C. T. W. N. Tumor-targeted low-dose radiation and immunotherapy in mouse models of melanoma. Int J Radiat Oncol Biol Phys. 2020;108:E556\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3281_CR39","doi-asserted-by":"publisher","unstructured":"Jhawar SR, et al. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer. J Immunother Cancer. 2023;11. https:\/\/doi.org\/10.1136\/jitc-2023-006780.","DOI":"10.1136\/jitc-2023-006780"},{"key":"3281_CR40","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/gt.2016.5","volume":"23","author":"DC Mansfield","year":"2016","unstructured":"Mansfield DC, et al. Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer. Gene Ther. 2016;23:357\u201368. https:\/\/doi.org\/10.1038\/gt.2016.5.","journal-title":"Gene Ther"},{"key":"3281_CR41","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1096\/fj.13-237222","volume":"28","author":"S Gholami","year":"2014","unstructured":"Gholami S, et al. Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer. FASEB J. 2014;28:676\u201382. https:\/\/doi.org\/10.1096\/fj.13-237222.","journal-title":"FASEB J"},{"key":"3281_CR42","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster MS, et al. Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39:599\u2013607. https:\/\/doi.org\/10.1200\/JCO.20.00605.","journal-title":"J Clin Oncol"},{"key":"3281_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","volume":"4","author":"H Aghajanian","year":"2022","unstructured":"Aghajanian H, Rurik JG, Epstein JA. CAR-based therapies: opportunities for immuno-medicine beyond cancer. Nat Metab. 2022;4:163\u20139. https:\/\/doi.org\/10.1038\/s42255-022-00537-5.","journal-title":"Nat Metab"},{"key":"3281_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41416-018-0341-1","volume":"120","author":"F Rataj","year":"2019","unstructured":"Rataj F, et al. High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. Br J Cancer. 2019;120:79\u201387. https:\/\/doi.org\/10.1038\/s41416-018-0341-1.","journal-title":"Br J Cancer"},{"key":"3281_CR45","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/0008-5472.CAN-18-3158","volume":"79","author":"EMV Forsberg","year":"2019","unstructured":"Forsberg EMV, et al. HER2 CAR-T cells eradicate uveal melanoma and T-cell therapy-resistant human melanoma in IL2 Transgenic NOD\/SCID IL2 receptor knockout mice. Cancer Res. 2019;79:899\u2013904. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-3158.","journal-title":"Cancer Res"},{"key":"3281_CR46","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/srep03571","volume":"4","author":"G Zhang","year":"2014","unstructured":"Zhang G, et al. Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep. 2014;4:3571. https:\/\/doi.org\/10.1038\/srep03571.","journal-title":"Sci Rep"},{"key":"3281_CR47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41408-020-00405-z","volume":"11","author":"AK Mishra","year":"2021","unstructured":"Mishra AK, Kemler I, Dingli D. Preclinical development of CD126 CAR-T cells with broad antitumor activity. Blood Cancer J. 2021;11:3. https:\/\/doi.org\/10.1038\/s41408-020-00405-z.","journal-title":"Blood Cancer J"},{"key":"3281_CR48","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-12-3913","volume":"73","author":"D Chinnasamy","year":"2013","unstructured":"Chinnasamy D, et al. Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. Cancer Res. 2013;73:3371\u201380. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-3913.","journal-title":"Cancer Res"},{"key":"3281_CR49","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1073\/pnas.1009069108","volume":"108","author":"P Schmidt","year":"2011","unstructured":"Schmidt P, et al. Eradication of melanomas by targeted elimination of a minor subset of tumor cells. Proc Natl Acad Sci U S A. 2011;108:2474\u20139. https:\/\/doi.org\/10.1073\/pnas.1009069108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3281_CR50","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1186\/s12885-017-3539-3","volume":"17","author":"DC Harrer","year":"2017","unstructured":"Harrer DC, et al. RNA-transfection of gamma\/delta T cells with a chimeric antigen receptor or an alpha\/beta T-cell receptor: a safer alternative to genetically engineered alpha\/beta T cells for the immunotherapy of melanoma. BMC Cancer. 2017;17:551. https:\/\/doi.org\/10.1186\/s12885-017-3539-3.","journal-title":"BMC Cancer"},{"key":"3281_CR51","doi-asserted-by":"publisher","unstructured":"Simon B, Harrer DC, Schuler-Thurner B, Schuler G, Uslu U. Arming T cells with a gp100-Specific TCR and a CSPG4-Specific CAR using combined DNA- and RNA-based receptor transfer. Cancers (Basel). 2019;11. https:\/\/doi.org\/10.3390\/cancers11050696.","DOI":"10.3390\/cancers11050696"},{"key":"3281_CR52","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/mt.2016.63","volume":"24","author":"T Gargett","year":"2016","unstructured":"Gargett T, et al. GD2-specific CAR T cells undergo potent activation and deletion following Antigen Encounter but can be protected from activation-induced cell death by PD-1 blockade. Mol Ther. 2016;24:1135\u201349. https:\/\/doi.org\/10.1038\/mt.2016.63.","journal-title":"Mol Ther"},{"key":"3281_CR53","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1158\/1078-0432.CCR-10-0043","volume":"16","author":"AS Lo","year":"2010","unstructured":"Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28\/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res. 2010;16:2769\u201380. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-0043.","journal-title":"Clin Cancer Res"},{"key":"3281_CR54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omto.2020.03.019","volume":"17","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, et al. B7-H3-Targeted CAR-T cells exhibit potent Antitumor effects on hematologic and solid tumors. Mol Ther Oncolytics. 2020;17:180\u20139. https:\/\/doi.org\/10.1016\/j.omto.2020.03.019.","journal-title":"Mol Ther Oncolytics"},{"key":"3281_CR55","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang M, et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics. 2020;10:7622\u201334. https:\/\/doi.org\/10.7150\/thno.43991.","journal-title":"Theranostics"},{"key":"3281_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-017-0548-2","volume":"11","author":"J Yu","year":"2018","unstructured":"Yu J, et al. Anti-GD2\/4-1BB chimeric antigen receptor T cell therapy for the treatment of Chinese melanoma patients. J Hematol Oncol. 2018;11:1. https:\/\/doi.org\/10.1186\/s13045-017-0548-2.","journal-title":"J Hematol Oncol"},{"key":"3281_CR57","first-page":"115","volume":"115","author":"SF Cramer","year":"1991","unstructured":"Cramer SF. The origin of epidermal melanocytes. Implications for the histogenesis of nevi and melanomas. Arch Pathol Lab Med. 1991;115:115\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"3281_CR58","unstructured":"Matthews NH, Li WQ, Qureshi AA, Weinstock MA, Cho E. In: Ward WH, Farma JM, editors. Cutaneous melanoma: etiology and therapy. 2017."},{"key":"3281_CR59","doi-asserted-by":"publisher","unstructured":"Yamaguchi Y, Hearing VJ. Melanocytes and their diseases. Cold Spring Harb Perspect Med. 2014;4. https:\/\/doi.org\/10.1101\/cshperspect.a017046.","DOI":"10.1101\/cshperspect.a017046"},{"key":"3281_CR60","doi-asserted-by":"publisher","first-page":"e13405","DOI":"10.1111\/dth.13405","volume":"33","author":"M Fioranelli","year":"2020","unstructured":"Fioranelli M, et al. A new medical imaging technique for diagnosing dermatologic diseases: a clue to treatment choices. Dermatol Ther. 2020;33:e13405. https:\/\/doi.org\/10.1111\/dth.13405.","journal-title":"Dermatol Ther"},{"key":"3281_CR61","first-page":"572","volume":"7","author":"A Sandru","year":"2014","unstructured":"Sandru A, Voinea S, Panaitescu E, Blidaru A. Survival rates of patients with metastatic malignant melanoma. J Med Life. 2014;7:572\u20136.","journal-title":"J Med Life"},{"key":"3281_CR62","doi-asserted-by":"publisher","first-page":"153303381879179","DOI":"10.1177\/1533033818791795","volume":"17","author":"C Naidoo","year":"2018","unstructured":"Naidoo C, Kruger CA, Abrahamse H. Photodynamic therapy for metastatic melanoma treatment: a review. Technol Cancer Res Treat. 2018;17:1533033818791795. https:\/\/doi.org\/10.1177\/1533033818791795.","journal-title":"Technol Cancer Res Treat"},{"key":"3281_CR63","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/0361-9230(83)90218-6","volume":"10","author":"H Barden","year":"1983","unstructured":"Barden H, Levine S. Histochemical observations on rodent brain melanin. Brain Res Bull. 1983;10:847\u201351. https:\/\/doi.org\/10.1016\/0361-9230(83)90218-6.","journal-title":"Brain Res Bull"},{"key":"3281_CR64","doi-asserted-by":"publisher","first-page":"1407143","DOI":"10.3389\/fonc.2024.1407143","volume":"14","author":"N Puebla-Osorio","year":"2024","unstructured":"Puebla-Osorio N, et al. Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy. Front Oncol. 2024;14:1407143. https:\/\/doi.org\/10.3389\/fonc.2024.1407143.","journal-title":"Front Oncol"},{"key":"3281_CR65","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/09553000500519808","volume":"81","author":"Y Ina","year":"2005","unstructured":"Ina Y, Sakai K. Activation of immunological network by chronic low-dose-rate irradiation in wild-type mouse strains: analysis of immune cell populations and surface molecules. Int J Radiat Biol. 2005;81:721\u20139. https:\/\/doi.org\/10.1080\/09553000500519808.","journal-title":"Int J Radiat Biol"},{"key":"3281_CR66","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1667\/RR1007.1","volume":"168","author":"L Lacoste-Collin","year":"2007","unstructured":"Lacoste-Collin L, et al. Effect of continuous irradiation with a very low dose of gamma rays on life span and the immune system in SJL mice prone to B-cell lymphoma. Radiat Res. 2007;168:725\u201332. https:\/\/doi.org\/10.1667\/RR1007.1.","journal-title":"Radiat Res"},{"key":"3281_CR67","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1016\/j.ymthe.2018.09.008","volume":"26","author":"C DeSelm","year":"2018","unstructured":"DeSelm C, et al. Low-dose Radiation Conditioning enables CAR T cells to mitigate Antigen escape. Mol Ther. 2018;26:2542\u201352. https:\/\/doi.org\/10.1016\/j.ymthe.2018.09.008.","journal-title":"Mol Ther"},{"key":"3281_CR68","doi-asserted-by":"publisher","first-page":"5396","DOI":"10.1182\/bloodadvances.2022009543","volume":"7","author":"AB Kim","year":"2023","unstructured":"Kim AB, et al. Intrinsic tumor resistance to CAR T cells is a dynamic transcriptional state that is exploitable with low-dose radiation. Blood Adv. 2023;7:5396\u2013408. https:\/\/doi.org\/10.1182\/bloodadvances.2022009543.","journal-title":"Blood Adv"},{"key":"3281_CR69","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/0008-5472.CAN-17-1788","volume":"78","author":"T Weiss","year":"2018","unstructured":"Weiss T, Weller M, Guckenberger M, Sentman CL, Roth P. NKG2D-Based CAR T cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. Cancer Res. 2018;78:1031\u201343. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1788.","journal-title":"Cancer Res"},{"key":"3281_CR70","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin L, et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019;10:4016. https:\/\/doi.org\/10.1038\/s41467-019-11869-4.","journal-title":"Nat Commun"},{"key":"3281_CR71","doi-asserted-by":"publisher","unstructured":"Boopathi E, Den RB, Thangavel C. Innate immune system in the context of radiation therapy for cancer. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15153972.","DOI":"10.3390\/cancers15153972"},{"key":"3281_CR72","doi-asserted-by":"publisher","first-page":"eabh4050","DOI":"10.1126\/sciadv.abh4050","volume":"8","author":"T Walle","year":"2022","unstructured":"Walle T, et al. Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8. Sci Adv. 2022;8:eabh4050. https:\/\/doi.org\/10.1126\/sciadv.abh4050.","journal-title":"Sci Adv"},{"key":"3281_CR73","doi-asserted-by":"publisher","first-page":"1361194","DOI":"10.3389\/fimmu.2024.1361194","volume":"15","author":"T Li","year":"2024","unstructured":"Li T, et al. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front Immunol. 2024;15:1361194. https:\/\/doi.org\/10.3389\/fimmu.2024.1361194.","journal-title":"Front Immunol"},{"key":"3281_CR74","doi-asserted-by":"publisher","first-page":"e1274","DOI":"10.1002\/cti2.1274","volume":"10","author":"M Daher","year":"2021","unstructured":"Daher M, Melo Garcia L, Li Y, Rezvani K. CAR-NK cells: the next wave of cellular therapy for cancer. Clin Transl Immunol. 2021;10:e1274. https:\/\/doi.org\/10.1002\/cti2.1274.","journal-title":"Clin Transl Immunol"},{"key":"3281_CR75","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41401-024-01260-5","volume":"45","author":"JZ Jiao","year":"2024","unstructured":"Jiao JZ, et al. Radiofrequency radiation reshapes tumor immune microenvironment into antitumor phenotype in pulmonary metastatic melanoma by inducing active transformation of tumor-infiltrating CD8(+) T and NK cells. Acta Pharmacol Sin. 2024;45:1492\u2013505. https:\/\/doi.org\/10.1038\/s41401-024-01260-5.","journal-title":"Acta Pharmacol Sin"},{"key":"3281_CR76","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1089\/cbr.2014.1702","volume":"29","author":"G Yang","year":"2014","unstructured":"Yang G, et al. Low-dose ionizing radiation induces direct activation of natural killer cells and provides a novel approach for adoptive cellular immunotherapy. Cancer Biother Radiopharm. 2014;29:428\u201334. https:\/\/doi.org\/10.1089\/cbr.2014.1702.","journal-title":"Cancer Biother Radiopharm"},{"key":"3281_CR77","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1093\/jrr\/rrs037","volume":"53","author":"CH Sonn","year":"2012","unstructured":"Sonn CH, et al. Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. J Radiat Res. 2012;53:823\u20139. https:\/\/doi.org\/10.1093\/jrr\/rrs037.","journal-title":"J Radiat Res"},{"key":"3281_CR78","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1667\/rr3123","volume":"161","author":"A Cheda","year":"2004","unstructured":"Cheda A, et al. Single low doses of X rays inhibit the development of experimental tumor metastases and trigger the activities of NK cells in mice. Radiat Res. 2004;161:335\u201340. https:\/\/doi.org\/10.1667\/rr3123.","journal-title":"Radiat Res"},{"key":"3281_CR79","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2307\/3580211","volume":"151","author":"S Hashimoto","year":"1999","unstructured":"Hashimoto S, et al. The suppression of metastases and the change in host immune response after low-dose total-body irradiation in tumor-bearing rats. Radiat Res. 1999;151:717\u201324.","journal-title":"Radiat Res"},{"key":"3281_CR80","doi-asserted-by":"publisher","first-page":"367","DOI":"10.3389\/fonc.2019.00367","volume":"9","author":"O Palata","year":"2019","unstructured":"Palata O, et al. Radiotherapy in Combination with Cytokine Treatment. Front Oncol. 2019;9:367. https:\/\/doi.org\/10.3389\/fonc.2019.00367.","journal-title":"Front Oncol"},{"key":"3281_CR81","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1158\/1078-0432.CCR-14-2676","volume":"21","author":"CM Zegers","year":"2015","unstructured":"Zegers CM, et al. Radiotherapy combined with the immunocytokine L19-IL2 provides long-lasting antitumor effects. Clin Cancer Res. 2015;21:1151\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2676.","journal-title":"Clin Cancer Res"},{"key":"3281_CR82","doi-asserted-by":"publisher","first-page":"670464","DOI":"10.3389\/fonc.2021.670464","volume":"11","author":"C Zhang","year":"2021","unstructured":"Zhang C, Liang Z, Ma S, Liu X. Radiotherapy and Cytokine Storm: risk and mechanism. Front Oncol. 2021;11:670464. https:\/\/doi.org\/10.3389\/fonc.2021.670464.","journal-title":"Front Oncol"},{"key":"3281_CR83","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12967-015-0397-0","volume":"13","author":"MM van den Heuvel","year":"2015","unstructured":"van den Heuvel MM, et al. NHS-IL2 combined with radiotherapy: preclinical rationale and phase Ib trial results in metastatic non-small cell lung cancer following first-line chemotherapy. J Transl Med. 2015;13:32. https:\/\/doi.org\/10.1186\/s12967-015-0397-0.","journal-title":"J Transl Med"},{"key":"3281_CR84","doi-asserted-by":"publisher","unstructured":"Yu CF, et al. Local Interleukin-12 treatment enhances the efficacy of radiation therapy by overcoming radiation-induced immune suppression. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms221810053.","DOI":"10.3390\/ijms221810053"},{"key":"3281_CR85","doi-asserted-by":"publisher","unstructured":"Clark PA, et al. In situ vaccination at a peripheral tumor site augments response against melanoma brain metastases. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-000809.","DOI":"10.1136\/jitc-2020-000809"},{"key":"3281_CR86","doi-asserted-by":"publisher","unstructured":"Shi W, Liu N, Lu H. Advancements and challenges in immunocytokines: a new arsenal against cancer. Acta Pharm Sin B. 2024;14:4649\u20134664. https:\/\/doi.org\/10.1016\/j.apsb.2024.07.024","DOI":"10.1016\/j.apsb.2024.07.024"},{"key":"3281_CR87","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/1573395054065115","volume":"1","author":"J Liu","year":"2005","unstructured":"Liu J, et al. Interleukin-12: an update on its immunological activities, signaling and regulation of gene expression. Curr Immunol Rev. 2005;1:119\u201337. https:\/\/doi.org\/10.2174\/1573395054065115.","journal-title":"Curr Immunol Rev"},{"key":"3281_CR88","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1200\/JCO.2004.10.045","volume":"22","author":"G Alatrash","year":"2004","unstructured":"Alatrash G, et al. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma. J Clin Oncol. 2004;22:2891\u2013900. https:\/\/doi.org\/10.1200\/JCO.2004.10.045.","journal-title":"J Clin Oncol"},{"key":"3281_CR89","doi-asserted-by":"publisher","first-page":"1218082","DOI":"10.3389\/fimmu.2023.1218082","volume":"14","author":"Y Fu","year":"2023","unstructured":"Fu Y, Tang R, Zhao X. Engineering cytokines for cancer immunotherapy: a systematic review. Front Immunol. 2023;14:1218082. https:\/\/doi.org\/10.3389\/fimmu.2023.1218082.","journal-title":"Front Immunol"},{"key":"3281_CR90","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.18632\/oncotarget.1853","volume":"5","author":"J Fallon","year":"2014","unstructured":"Fallon J, et al. The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014;5:1869\u201384. https:\/\/doi.org\/10.18632\/oncotarget.1853.","journal-title":"Oncotarget"},{"key":"3281_CR91","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1158\/1078-0432.CCR-18-1512","volume":"25","author":"J Strauss","year":"2019","unstructured":"Strauss J, et al. First-in-human phase I trial of a tumor-targeted cytokine (NHS-IL12) in subjects with metastatic solid tumors. Clin Cancer Res. 2019;25:99\u2013109. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1512.","journal-title":"Clin Cancer Res"},{"key":"3281_CR92","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-023-00206-6","volume":"23","author":"A Mullard","year":"2024","unstructured":"Mullard A. Tumour-infiltrating lymphocyte cancer therapy nears FDA finish line. Nat Rev Drug Discov. 2024;23:3\u20137. https:\/\/doi.org\/10.1038\/d41573-023-00206-6.","journal-title":"Nat Rev Drug Discov"},{"key":"3281_CR93","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1200\/JCO.21.00612","volume":"39","author":"AA Sarnaik","year":"2021","unstructured":"Sarnaik AA, et al. Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma. J Clin Oncol. 2021;39:2656\u201366. https:\/\/doi.org\/10.1200\/JCO.21.00612.","journal-title":"J Clin Oncol"},{"key":"3281_CR94","doi-asserted-by":"publisher","unstructured":"Chesney J, et al. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study. J Immunother Cancer. 2022;10. https:\/\/doi.org\/10.1136\/jitc-2022-005755.","DOI":"10.1136\/jitc-2022-005755"},{"key":"3281_CR95","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan MW, et al. Tumor-infiltrating lymphocyte therapy or Ipilimumab in Advanced Melanoma. N Engl J Med. 2022;387:2113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa2210233.","journal-title":"N Engl J Med"},{"key":"3281_CR96","doi-asserted-by":"publisher","unstructured":"van den Berg JH, et al. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-000848.","DOI":"10.1136\/jitc-2020-000848"},{"key":"3281_CR97","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran SS, et al. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017;18:792\u2013802. https:\/\/doi.org\/10.1016\/S1470-2045(17)30251-6.","journal-title":"Lancet Oncol"},{"key":"3281_CR98","doi-asserted-by":"publisher","unstructured":"Patel SP, Forget MA, Kreidieh FY, Pelster M, Davies MA, Amaria RN, Gombos DS, Bernatchez C. Tumor infiltrating lymphocyte (TIL) harvest and ex vivo expansion from primary and metastatic (met) uveal melanoma (UM) tumors. J Clin Oncol. 2023;41. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.95.","DOI":"10.1200\/JCO.2023.41.16_suppl.95"},{"key":"3281_CR99","doi-asserted-by":"publisher","unstructured":"Obertopp N, Thomas A, Ali J, Blauvelt J, Hall A, Enderling H, Pilon-Thomas S. Utilizing radiation to improve adoptive cell therapy with tumor infiltrating lymphocytes. J Immunother Cancer. 2024;2024 12. https:\/\/doi.org\/10.1136\/jitc-2024-ITOC10.55.","DOI":"10.1136\/jitc-2024-ITOC10.55"},{"key":"3281_CR100","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka RH, et al. Talimogene Laherparepvec improves durable response rate in patients with Advanced Melanoma. J Clin Oncol. 2015;33:2780\u20138. https:\/\/doi.org\/10.1200\/JCO.2014.58.3377.","journal-title":"J Clin Oncol"},{"key":"3281_CR101","doi-asserted-by":"publisher","unstructured":"Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-001486.","DOI":"10.1136\/jitc-2020-001486"},{"key":"3281_CR102","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2021006631","volume":"6","author":"J Cook","year":"2022","unstructured":"Cook J, et al. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma. Blood Adv. 2022;6:3268\u201379. https:\/\/doi.org\/10.1182\/bloodadvances.2021006631.","journal-title":"Blood Adv"},{"key":"3281_CR103","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13104-020-05068-4","volume":"13","author":"A Tilgase","year":"2020","unstructured":"Tilgase A, et al. Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines. BMC Res Notes. 2020;13:222. https:\/\/doi.org\/10.1186\/s13104-020-05068-4.","journal-title":"BMC Res Notes"},{"key":"3281_CR104","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1089\/hum.2018.107","volume":"30","author":"M Garcia","year":"2019","unstructured":"Garcia M, et al. A phase 1 trial of Oncolytic Adenovirus ICOVIR-5 administered intravenously to cutaneous and uveal melanoma patients. Hum Gene Ther. 2019;30:352\u201364. https:\/\/doi.org\/10.1089\/hum.2018.107.","journal-title":"Hum Gene Ther"},{"key":"3281_CR105","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1074\/jbc.M409934200","volume":"280","author":"LS Hart","year":"2005","unstructured":"Hart LS, et al. The adenovirus E4orf6 protein inhibits DNA double strand break repair and radiosensitizes human tumor cells in an E1B-55K-independent manner. J Biol Chem. 2005;280:1474\u201381. https:\/\/doi.org\/10.1074\/jbc.M409934200.","journal-title":"J Biol Chem"},{"key":"3281_CR106","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1182\/blood-2007-01-065573","volume":"110","author":"A Goel","year":"2007","unstructured":"Goel A, et al. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood. 2007;110:2342\u201350. https:\/\/doi.org\/10.1182\/blood-2007-01-065573.","journal-title":"Blood"},{"key":"3281_CR107","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/cgt.2013.43","volume":"20","author":"H Li","year":"2013","unstructured":"Li H, Nakashima H, Decklever TD, Nace RA, Russell SJ. HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy. Cancer Gene Ther. 2013;20:478\u201385. https:\/\/doi.org\/10.1038\/cgt.2013.43.","journal-title":"Cancer Gene Ther"},{"key":"3281_CR108","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1089\/hum.2011.158","volume":"23","author":"M Opyrchal","year":"2012","unstructured":"Opyrchal M, et al. Effective radiovirotherapy for malignant gliomas by using oncolytic measles virus strains encoding the sodium iodide symporter (MV-NIS). Hum Gene Ther. 2012;23:419\u201327. https:\/\/doi.org\/10.1089\/hum.2011.158.","journal-title":"Hum Gene Ther"},{"key":"3281_CR109","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ebiom.2019.10.032","volume":"49","author":"G Vijayakumar","year":"2019","unstructured":"Vijayakumar G, Palese P, Goff PH. Oncolytic Newcastle Disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. EBioMedicine. 2019;49:96\u2013105. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.032.","journal-title":"EBioMedicine"},{"key":"3281_CR110","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","volume":"356","author":"S Siva","year":"2015","unstructured":"Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356:82\u201390. https:\/\/doi.org\/10.1016\/j.canlet.2013.09.018.","journal-title":"Cancer Lett"},{"key":"3281_CR111","doi-asserted-by":"publisher","unstructured":"Hoefsmit EP, et al. Comprehensive analysis of cutaneous and uveal melanoma liver metastases. J Immunother Cancer. 2020;8. https:\/\/doi.org\/10.1136\/jitc-2020-001501.","DOI":"10.1136\/jitc-2020-001501"},{"key":"3281_CR112","doi-asserted-by":"publisher","unstructured":"Bakhoum MF, Esmaeli B. Molecular characteristics of uveal melanoma: insights from the cancer genome atlas (TCGA) project. Cancers (Basel). 2019;11. https:\/\/doi.org\/10.3390\/cancers11081061.","DOI":"10.3390\/cancers11081061"},{"key":"3281_CR113","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385:1196\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2103485.","journal-title":"N Engl J Med"},{"key":"3281_CR114","doi-asserted-by":"publisher","first-page":"10152","DOI":"10.1073\/pnas.0702916104","volume":"104","author":"ED Kirson","year":"2007","unstructured":"Kirson ED, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104:10152\u20137. https:\/\/doi.org\/10.1073\/pnas.0702916104.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3281_CR115","doi-asserted-by":"publisher","first-page":"18046","DOI":"10.1038\/srep18046","volume":"5","author":"M Giladi","year":"2015","unstructured":"Giladi M, et al. Mitotic spindle disruption by Alternating Electric fields leads to Improper chromosome segregation and mitotic catastrophe in Cancer cells. Sci Rep. 2015;5:18046. https:\/\/doi.org\/10.1038\/srep18046.","journal-title":"Sci Rep"},{"key":"3281_CR116","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s10585-009-9262-y","volume":"26","author":"ED Kirson","year":"2009","unstructured":"Kirson ED, et al. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin Exp Metastasis. 2009;26:633\u201340. https:\/\/doi.org\/10.1007\/s10585-009-9262-y.","journal-title":"Clin Exp Metastasis"},{"key":"3281_CR117","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.trecan.2017.09.006","volume":"3","author":"LL van der Woude","year":"2017","unstructured":"van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJ. M. migrating into the Tumor: a Roadmap for T cells. Trends Cancer. 2017;3:797\u2013808. https:\/\/doi.org\/10.1016\/j.trecan.2017.09.006.","journal-title":"Trends Cancer"},{"key":"3281_CR118","doi-asserted-by":"publisher","first-page":"62267","DOI":"10.18632\/oncotarget.11407","volume":"7","author":"EH Kim","year":"2016","unstructured":"Kim EH, et al. Biological effect of an alternating electric field on cell proliferation and synergistic antimitotic effect in combination with ionizing radiation. Oncotarget. 2016;7:62267\u201379. https:\/\/doi.org\/10.18632\/oncotarget.11407.","journal-title":"Oncotarget"},{"key":"3281_CR119","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13014-017-0941-6","volume":"12","author":"M Giladi","year":"2017","unstructured":"Giladi M, et al. Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiat Oncol. 2017;12:206. https:\/\/doi.org\/10.1186\/s13014-017-0941-6.","journal-title":"Radiat Oncol"},{"key":"3281_CR120","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fonc.2020.00411","volume":"10","author":"F Bokstein","year":"2020","unstructured":"Bokstein F, et al. Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for newly diagnosed glioblastoma: a prospective safety and feasibility study. Front Oncol. 2020;10:411. https:\/\/doi.org\/10.3389\/fonc.2020.00411.","journal-title":"Front Oncol"},{"key":"3281_CR121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.0300-9475.2005.01531.x","volume":"61","author":"AE Pedersen","year":"2005","unstructured":"Pedersen AE, et al. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol. 2005;61:147\u201356. https:\/\/doi.org\/10.1111\/j.0300-9475.2005.01531.x.","journal-title":"Scand J Immunol"},{"key":"3281_CR122","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1126\/science.8097338","volume":"260","author":"CS Hsieh","year":"1993","unstructured":"Hsieh CS, et al. Development of TH1 CD4\u2009+\u2009T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547\u20139. https:\/\/doi.org\/10.1126\/science.8097338.","journal-title":"Science"},{"key":"3281_CR123","doi-asserted-by":"publisher","first-page":"5521","DOI":"10.4049\/jimmunol.168.11.5521","volume":"168","author":"CS Schmidt","year":"2002","unstructured":"Schmidt CS, Mescher MF. Peptide antigen priming of naive, but not memory, CD8 T cells requires a third signal that can be provided by IL-12. J Immunol. 2002;168:5521\u20139. https:\/\/doi.org\/10.4049\/jimmunol.168.11.5521.","journal-title":"J Immunol"},{"key":"3281_CR124","doi-asserted-by":"publisher","first-page":"155932581983214","DOI":"10.1177\/1559325819832144","volume":"17","author":"S Wang","year":"2019","unstructured":"Wang S, et al. Exposure to low-dose Radiation enhanced the Antitumor Effect of a dendritic cell vaccine. Dose Response. 2019;17:1559325819832144. https:\/\/doi.org\/10.1177\/1559325819832144.","journal-title":"Dose Response"},{"key":"3281_CR125","doi-asserted-by":"publisher","first-page":"43039","DOI":"10.18632\/oncotarget.9915","volume":"7","author":"W Zheng","year":"2016","unstructured":"Zheng W, et al. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. Oncotarget. 2016;7:43039\u201351. https:\/\/doi.org\/10.18632\/oncotarget.9915.","journal-title":"Oncotarget"},{"key":"3281_CR126","doi-asserted-by":"publisher","unstructured":"Cadena A, et al. Radiation and anti-cancer vaccines: a winning combination. Vaccines (Basel). 2018;6. https:\/\/doi.org\/10.3390\/vaccines6010009.","DOI":"10.3390\/vaccines6010009"},{"key":"3281_CR127","doi-asserted-by":"publisher","unstructured":"Liu D, Che X, Wang X, Ma C, Wu G. Tumor vaccines: unleashing the power of the immune system to fight cancer. Pharmaceuticals (Basel). 2023;16. https:\/\/doi.org\/10.3390\/ph16101384.","DOI":"10.3390\/ph16101384"},{"key":"3281_CR128","doi-asserted-by":"publisher","unstructured":"Gupta M, et al. Recent advances in cancer vaccines: challenges, achievements, and futuristic prospects. Vaccines (Basel). 2022;10. https:\/\/doi.org\/10.3390\/vaccines10122011.","DOI":"10.3390\/vaccines10122011"},{"key":"3281_CR129","doi-asserted-by":"publisher","unstructured":"Verma C, et al. Cancer vaccines in the immunotherapy era: promise and potential. Vaccines (Basel). 2023;11. https:\/\/doi.org\/10.3390\/vaccines11121783.","DOI":"10.3390\/vaccines11121783"},{"key":"3281_CR130","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-022-01247-x","volume":"15","author":"J Liu","year":"2022","unstructured":"Liu J, et al. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022;15:28. https:\/\/doi.org\/10.1186\/s13045-022-01247-x.","journal-title":"J Hematol Oncol"},{"key":"3281_CR131","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/PPO.0b013e3181eb33d7","volume":"16","author":"DT Le","year":"2010","unstructured":"Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approaches. Cancer J. 2010;16:304\u201310. https:\/\/doi.org\/10.1097\/PPO.0b013e3181eb33d7.","journal-title":"Cancer J"},{"key":"3281_CR132","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-016-0160-y","volume":"4","author":"H Khong","year":"2016","unstructured":"Khong H, Overwijk WW. Adjuvants for peptide-based cancer vaccines. J Immunother Cancer. 2016;4:56. https:\/\/doi.org\/10.1186\/s40425-016-0160-y.","journal-title":"J Immunother Cancer"},{"key":"3281_CR133","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.pharmthera.2016.05.004","volume":"165","author":"A Tiptiri-Kourpeti","year":"2016","unstructured":"Tiptiri-Kourpeti A, Spyridopoulou K, Pappa A, Chlichlia K. DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016;165:32\u201349. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.05.004.","journal-title":"Pharmacol Ther"},{"key":"3281_CR134","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1158\/1078-0432.CCR-20-0245","volume":"27","author":"J Jou","year":"2021","unstructured":"Jou J, Harrington KJ, Zocca MB, Ehrnrooth E, Cohen EE. W. The changing Landscape of Therapeutic Cancer vaccines-Novel platforms and Neoantigen Identification. Clin Cancer Res. 2021;27:689\u2013703. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-0245.","journal-title":"Clin Cancer Res"},{"key":"3281_CR135","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ijrobp.2012.06.020","volume":"84","author":"SC Formenti","year":"2012","unstructured":"Formenti SC, Demaria S. Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat Oncol Biol Phys. 2012;84:879\u201380. https:\/\/doi.org\/10.1016\/j.ijrobp.2012.06.020.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3281_CR136","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862\u201370. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.09.012.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3281_CR137","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","volume":"2","author":"HJ Kim","year":"2014","unstructured":"Kim HJ, Cantor H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res. 2014;2:91\u20138. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0216.","journal-title":"Cancer Immunol Res"},{"key":"3281_CR138","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2217\/imt.15.65","volume":"7","author":"SN Seyedin","year":"2015","unstructured":"Seyedin SN, et al. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015;7:967\u201380. https:\/\/doi.org\/10.2217\/imt.15.65.","journal-title":"Immunotherapy"},{"key":"3281_CR139","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC. Role of local Radiation Therapy in Cancer Immunotherapy. JAMA Oncol. 2015;1:1325\u201332. https:\/\/doi.org\/10.1001\/jamaoncol.2015.2756.","journal-title":"JAMA Oncol"},{"key":"3281_CR140","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1748-717X-9-180","volume":"9","author":"M Fotin-Mleczek","year":"2014","unstructured":"Fotin-Mleczek M, et al. mRNA-based vaccines synergize with radiation therapy to eradicate established tumors. Radiat Oncol. 2014;9:180. https:\/\/doi.org\/10.1186\/1748-717X-9-180.","journal-title":"Radiat Oncol"},{"key":"3281_CR141","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"AA Lugade","year":"2005","unstructured":"Lugade AA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516\u201323. https:\/\/doi.org\/10.4049\/jimmunol.174.12.7516.","journal-title":"J Immunol"},{"key":"3281_CR142","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.CAN-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang X, et al. Suppression of type I IFN Signaling in Tumors mediates resistance to Anti-PD-1 treatment that can be overcome by Radiotherapy. Cancer Res. 2017;77:839\u201350. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-3142.","journal-title":"Cancer Res"},{"key":"3281_CR143","doi-asserted-by":"publisher","unstructured":"Levy R, Reagan PM, Friedberg JW, Bartlett NL, Gordon LI, Leung A, Peterkin J, Xing B, Coffman R, Janssen R, Candia A, Khodadoust M, Frank MJ, Long SR, Czerwinski DK, Chu M. SD-101, a novel class C CpG-Oligodeoxynucleotide (ODN) toll-like receptor 9 (TLR9) agonist, given with low dose radiation for untreated low grade B-cell lymphoma: interim results of a phase 1\/2 Trial. Blood. 2016;128:2974. https:\/\/doi.org\/10.1182\/blood.V128.22.2974.2974","DOI":"10.1182\/blood.V128.22.2974.2974"},{"key":"3281_CR144","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2203\/dose-response.06-108.Liu","volume":"5","author":"SZ Liu","year":"2006","unstructured":"Liu SZ. Cancer control related to stimulation of immunity by low-dose radiation. Dose Response. 2006;5:39\u201347. https:\/\/doi.org\/10.2203\/dose-response.06-108.Liu.","journal-title":"Dose Response"},{"key":"3281_CR145","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.cellimm.2007.02.009","volume":"244","author":"H Ren","year":"2006","unstructured":"Ren H, et al. Augmentation of innate immunity by low-dose irradiation. Cell Immunol. 2006;244:50\u20136. https:\/\/doi.org\/10.1016\/j.cellimm.2007.02.009.","journal-title":"Cell Immunol"},{"key":"3281_CR146","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/09553000500531886","volume":"81","author":"R Pandey","year":"2005","unstructured":"Pandey R, Shankar BS, Sharma D, Sainis KB. Low dose radiation induced immunomodulation: effect on macrophages and CD8+ T cells. Int J Radiat Biol. 2005;81:801\u201312. https:\/\/doi.org\/10.1080\/09553000500531886.","journal-title":"Int J Radiat Biol"},{"key":"3281_CR147","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1080\/09553000902748609","volume":"85","author":"DS Gridley","year":"2009","unstructured":"Gridley DS, et al. Low-dose, low-dose-rate proton radiation modulates CD4(+) T cell gene expression. Int J Radiat Biol. 2009;85:250\u201361. https:\/\/doi.org\/10.1080\/09553000902748609.","journal-title":"Int J Radiat Biol"},{"key":"3281_CR148","first-page":"225","volume":"32","author":"PYQJFLRHC LI","year":"2012","unstructured":"LI. PYQJFLRHC. W. X. effects of low dose X-ray irradiation on antigen presentation and IL-12 secretion in human dendritic cells in vitro. Chin J Radiological Med Prot. 2012;32:225\u20139.","journal-title":"Chin J Radiological Med Prot"},{"key":"3281_CR149","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3760\/cma.j.issn.0254-5098.2013.05.005","volume":"33","author":"JQ-s LI Xiao","year":"2013","unstructured":"Li X, Jiang Q, Li F, Lv J, Wang S, He R, Zou Y, Sun S, Wang C, Liu J. Effect of low dose X-ray irradiation on migration of human dendrite cells and underlying mechanism. Chin J Radiological Med Prot. 2013;33:476\u20139. https:\/\/doi.org\/10.3760\/cma.j.issn.0254-5098.2013.05.005.","journal-title":"Chin J Radiological Med Prot"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03281-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03281-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03281-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T22:53:21Z","timestamp":1738191201000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03281-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":149,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3281"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03281-2","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JWW: Accuray (SAB, consulting), Alpine Immune Science (SAB, consulting, equity), Boehringer Ingelheim (SAB, consulting), Checkmate Pharmaceuticals (SAB, consulting, equity), China Medical Tribune (SAB, consulting), Genentech (SAB, consulting), GI Innovation (SAB, consulting), Kezar Life Sciences (consulting, SAB), Legion Healthcare Partners (SAB, consulting), Life Science Dynamic Limited (SAB, consulting), McKesson Corporation (SAB, consulting), Molecular Match (equity), Nanorobotix (SAB, consulting), OligoImmune (founder), Roche (SAB, consulting), Roche Molecular Systems (SAB, consulting), Nanobiotix (Research grant, Travel expenses, SAB), BMS (Research grant), Merck (Research grant), Varian (Research grant, Travel expenses, clinical sponsored research), Reflexion (Research grant, Travel expenses, Stock options, SAB), Hotspot Therapeutics (Research grant), Gilead (Research grant), Novocure (SAB), Oncoresponse (SAB, Stock options), Astra Zeneca (consultant, Research grant), Bayer Healthcare (Research grant), Kiromic (Research grant), Alkermes (Research grant, SAB), Artidis (Research grant), Sciclone (Research grant), Takeda (Research grant), Pebble Life Science (Research grant). MD Anderson has a trademark designation for RadScopalTM technique. The remaining authors declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}